13 Dead In India’s Nipah Outbreak; CEPI Announces $25M Over 5 Years For Vaccine Development

CIDRAP News: Nipah death toll in India hits 12 as CEPI funds vaccine efforts
“…[Thursday] the Coalition for Epidemic Preparedness Innovations (CEPI) announced a $25 million collaboration with two pharmaceutical companies to develop a vaccine against the disease, one of the group’s priority diseases…” (Schnirring, 5/24).

Quartz: The latest outbreak of a deadly virus has scientists racing to create a vaccine
“…CEPI said it would grant up to $25 million over the next five years to U.S. pharma firms Profectus BioSciences and Emergent BioSolutions to advance the development of a vaccine against the viral infection, which has proved to be fatal in 70 percent of cases…” (Thomas, 5/25).

Reuters: India steps up hunt for origin of mysterious brain-damaging virus
“India began a fresh round of tests to trace the origin of a rare brain-damaging virus that has killed 13 people, a health official said on Monday, as initial tests on animals suspected of carrying the Nipah virus showed no sign of the disease…” (Patnaik/Jose, 5/28).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.